You are here

Discovery of novel Alzheimer's Disease-specific antigens/epitopes and their captu

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AG047694-01
Agency Tracking Number: R43AG047694
Amount: $224,528.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10151 Pacific Mesa Blvd.
SAN DIEGO, CA 92121-4329
United States
DUNS: 186489899
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 XIAOMIN FAN
 (858) 768-8107
 xfan@avantgen.com
Business Contact
 CATHERINE WOODS
Phone: (858) 775-7033
Email: cmwoods@avantgen.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Since substantial neuronal loss has already occurred by the time Alzheimer's Disease (AD) manifests clinically, considerable research has been directed towards developing biomarkers for the reliable diagnosis of mild ADand the prodromal stage of mild cognitive impairment. The best studied biomarkers, A1-42 peptide and tau/P-tau, can distinguish cohorts of moderate versus mild AD or MCI subjects, but values vary considerably on an individual basis. Therefore, there is anurgent need for biomarkers with greater specificity and sensitivity. Here we propose to use our proprietary yeast display antibody library to differentially screen for antibody clones that bind to antigens whose structure/epitopes are markedly altered inAD compared to age-matched control CSF. The yeast clones harvested by FACS will be used to generate a yeast cell-based microarray to probe individual AD and normal subject CSF samples to identify those clones that exhibit marked differences in binding to

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government